Abstract

The UCLA CANCER GENE MEDICINE TRAINING GRANT T32 CA75956 serves as the principal translational research training mechanism at this institution for gene-based approaches to cancer therapy. The UCLA Human Gene Medicine Program (HGMP) is a scientifically and clinically robust interdisciplinary program with a major emphasis in cancer. Of the 31 clinical trials into which 235 patients have been entered, 90 percent were cancer-directed. In addition to providing scientific and regulatory oversight for gene therapy trials, the HGMP supervises a GMP Gene Therapy Core Laboratory, has awarded 45 seed grants over the last six years, hosts a score of educational seminars and symposiums annually and provides formal training and certification for investigators participating in gene medicine trials. ? ? It is against this background of a very successful gene medicine program that this T32 training grant serves as the foundation for integrated training in basic, translational and clinical conduct of cancer gene medicine research. The program provides trainees with a solid background in cancer biology, gene transfer and expression, animal models, clinical trials design and conduct and the responsible conduct of research. In particular, this program stimulates trainees to bridge basic and clinical research. The Training Faculty is composed of 18 investigators from 10 departments who provide scientific programs with considerable depth and breadth for our trainees. ? ? As the T32 enters year 05 of funding, 10 trainees have or are being supported through the training vehicle. These postdoctoral fellows fall into two broad categories - MD trainees in surgical, medical or pediatric Oncology and Ph.D. trainees with backgrounds in molecular biology, immunology and genetics. Our aggressive recruitment strategy has also yielded a trainee group with broadly representative demographics - 3 women, 1 African-American and 2 Latino(a). We request support to continue this successful training for years 6-10.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
5T32CA075956-08
Application #
6791182
Study Section
Special Emphasis Panel (ZCA1-GRB-N (M1))
Program Officer
Gorelic, Lester S
Project Start
1997-09-30
Project End
2007-06-30
Budget Start
2004-07-01
Budget End
2005-06-30
Support Year
8
Fiscal Year
2004
Total Cost
$233,016
Indirect Cost

  Institution

Name
University of California Los Angeles
Department
Surgery
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095

  Publications

Quatromoni, Jon G; Morris, Lilah F; Donahue, Timothy R et al. (2011) T cell receptor transgenic lymphocytes infiltrating murine tumors are not induced to express foxp3. J Hematol Oncol 4:48
Morris, Lilah F; Ribas, Antoni (2007) Therapeutic cancer vaccines. Surg Oncol Clin N Am 16:819-31, ix
Yin, Dong; Komatsu, Naoki; Miller, Carl W et al. (2007) KLF6: mutational analysis and effect on cancer cell proliferation. Int J Oncol 30:65-72
Schumacher, Lana Y; Vo, Dan D; Garban, Hermes J et al. (2006) Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade). J Immunol 176:4757-65
Butterfield, Lisa H; Ribas, Antoni; Dissette, Vivian B et al. (2006) A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res 12:2817-25
Ribas, Antoni; Vo, Dan D; Weeks, David L et al. (2006) Broad antitumor protection by dendritic cells administered to CD8alpha knock out mice. Cancer Immunol Immunother 55:663-71
Lai, Albert; Le, Dung-Nghi; Paznekas, William A et al. (2006) Oculodentodigital dysplasia connexin43 mutations result in non-functional connexin hemichannels and gap junctions in C6 glioma cells. J Cell Sci 119:532-41
Jones, Letetia C; Tefferi, Ayalew; Vuong, Peter T et al. (2005) Detection of aberrant gene expression in CD34+ hematopoietic stem cells from patients with agnogenic myeloid metaplasia using oligonucleotide microarrays. Stem Cells 23:631-7
Jones, Letetia C; Tefferi, Ayalew; Idos, Gregory E et al. (2004) RARbeta2 is a candidate tumor suppressor gene in myelofibrosis with myeloid metaplasia. Oncogene 23:7846-53
Ribas, Antoni; Wargo, Jennifer A; Comin-Anduix, Begonya et al. (2004) Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells. J Immunol 172:4762-9

Showing the most recent 10 out of 25 publications